ERBB2 and breast cancer: We present the data from a molecular sub-study that determined telomere length in the CNIO-BR-003/GEICAM-10/10 clinical trial, in which early HER2-negative breast cancer patients received single-agent weekly paclitaxel (standard arm) or weekly paclitaxel plus nintedanib.